Siegall Clay B's Form 4 filing
Immunome Inc. (IMNM) · filed Feb 3, 2025
- Accession no.
- 0001415889-25-002824
- Filed
- Feb 3, 2025
- Trade date
- Jan 31, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $1.16M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Siegall Clay BCIK 0001167496 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2025 | Common Stock | PPurchaseAcquired | +150,000 | $7.75 | +$1,162,500 | 669,636 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.